Group items matching

in title, tags, annotations or url

The technology – invented by Mount Sinai scientists Dr. Ian Rogers and Dr. Robert Casper – offers a proprietary method to create multi-potent stem cells (MPSCs) from human umbilical cord blood.

With MaRS Innovation's participation, we are optimistic we will succeed."

Our partnership with MaRS Innovation on developing methods for using stem cells for diseases such as diabetes will allow us to work towards advancing care for these critical conditions." With the launch of this first exciting opportunity, MaRS Innovation has embarked on a journey to transform the Toronto-based research enterprise into a successful commercialization cluster.

MaRS Innovation is building its own internal infrastructure to support intellectual property and market due diligence to identify the most promising commercial opportunities. MaRS Innovation is dedicated to converting the outstanding science of its member institutions into products and services, making a significant contribution to Canada’s future economic outlook and the quality of life for Canadians and others around the world

“We are deeply committed to creating a powerful engine for commercialization that brings together an experienced team to identify and validate market opportunities, develop technologies to market requirements and build the linkages that will advance the exceptional research of all of our institutional members,” added Dr. Hofstein. “We look forward to announcing additional technologies to add to our pipeline over the next several weeks.”

* Social Tech Training, or My Charity Connects * Innovation Parkour * Social Mastermind // Social Media for Social Change * The Skills Exchange * Defining and Measuring Social Success And in the evenings, Net Change brings unique community collaborations like: * Mobile Monday takes a social change perspective * Toronto's Internet Town Hall at the Gladstone Hotel * Cocktails and Inspiration: a discussion on profound innovation and social change with Eric Young in conversation with Bill White. * Wired Wednesday gets a dose of Web of Change * Refresh Events encourages collaborative partnerships

Net Change's ticketed and free events are taking place at the MaRS Centre. For more information on events and how to be involved, check out http://www.netchangeweek.ca.

A key strategic focus of the SickKids Research Institute is the commercialization of research findings-translating discoveries into new technologies and treatments to improve the understanding and treatment of diseases that affect children.

"An environment like the Discovery District allows research institutes and the University of Toronto and its affiliated hospitals to work together to promote research and its application," she explains.

One of the unique aspects of Toronto is its open, collaborative environment. Individual institutes are not fighting each other for funding resources. This collaborative nature is what people comment on when they come here." A Toronto location provides other advantages too, she says. "There is a strong university and college environment, which provides a great pool from which to draw talent. There is strong support from all three levels of government. And there is strong philanthropic support, which is important." Dr. Rossant says working for the Hospital for Sick Children has been very gratifying.

Dr. Rossant is also looking forward to the opening of the new research and education building going up in the Discovery District. "The Research Institute currently has 2,000 people spread across the Discovery District and the new building will bring us all together and allow us to interact in new ways."

W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto

MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.